Benchmark analyst Bruce Jackson raised the firm’s price target on Exact Sciences to $96 from $81 and keeps a Buy rating on the shares. Exact Sciences’s investor day event was preceded by the release of positive clinical data for the company’s Cologuard 2.0, which demonstrated notable improvement in the false positive rate vs. the original test, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EXAS:
- Credit Suisse keeps Neutral on Exact after BLUE-C data readout for Cologuard 2.0
- Exact’s BLUE-C top-line data beat expectations, says William Blair
- Exact Sciences’ Advanced Adenoma data ‘disappointing,’ says Stifel
- Exact Sciences signs research agreements with Broad Institute of MIT and Harvard
- Exact Sciences announces results from BLUE-C study